Resonance Health Ltd
AASX:RHT0.08
AUD
+0.01
(+6.49%)
Resonance Health Ltd
ASX:RHT
(Australian Securities Exchange)
Recent
price
0.08
P/E
ratio
158.93
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Resonance Health Limited, an Australia-based healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) and related services for non-invasive MRI analysis of liver and heart iron concentration, liver fat assessment, and clinical trial support; its core products include FerriScan, a non-invasive MRI-based solution for quantifying liver iron concentration; FerriSmart, an AI-powered tool for automated real-time assessment of liver iron concentration; HepaFatScan and HepaFatSmart, MRI-based and AI-driven solutions for liver fat measurement; LiverSmart, a multi-parametric device combining FerriSmart and HepaFatSmart; CardiacT2, a service for assessing heart iron loading alongside FerriScan; and high-quality phantoms for MRI machine calibration and quality assurance. The company operates through SaMD, Resonance Clinical, and TrialsWest segments, serving clinicians managing diseases such as thalassemia, hemochromatosis, and hepatic steatosis, as well as pharmaceutical and biotech firms for clinical trials; it conducts business in Australia, Asia Pacific, North America, Europe, the Middle East, and Africa. Founded in 1987 and headquartered in Burswood, Australia, Resonance Health recently completed the acquisition of clinical research organization TrialsWest in June 2024 for A$8 million to expand its clinical trial capabilities, including site management, imaging analysis, and project support; it secured a major contract in November 2024 with Sun Pharmaceutical Industries to act as local Australian sponsor for a global clinical trial, generating an estimated A$13.8 million in revenue over 24 months through TrialsWest; and continues to pursue additional trial sites and complementary acquisitions to strengthen its position in the global pharma and clinical research markets.